Publicacións (157) Publicacións de ANTONIO CASADO HERRÁEZ

2024

  1. Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients

    Cytokine, Vol. 177

2023

  1. Evaluación del Miedo a la Recurrencia del cáncer en español: el Cuestionario de Miedo a la Recurrencia del Cáncer y Escala General del Miedo a la Recurrencia del Cáncer: un estudio piloto

    Psicooncología: investigación y clínica biopsicosocial en oncología, Vol. 20, Núm. 1, pp. 155-173

2022

  1. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

    Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48

2021

  1. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer

    Oncologist, Vol. 26, Núm. 4, pp. e658-e668

  2. Complete Spontaneous Regression of Lung Metastases after Resection of CIC-Rearranged Sarcoma: A Case Report

    Case Reports in Oncology, Vol. 14, Núm. 1, pp. 152-159

  3. Cáncer ginecológico en la anciana

    Revisiones en Cancer, Vol. 35, Núm. 5, pp. 209-217

  4. Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? a study protocol

    Cancers, Vol. 13, Núm. 1, pp. 1-14

  5. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report

    World Journal of Surgical Oncology, Vol. 19, Núm. 1

  6. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 922-930

2020

  1. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

    International Journal of Gynecological Cancer, Vol. 30, Núm. 10, pp. 1633-1637

  2. Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

    Angiogenesis, Vol. 23, Núm. 4, pp. 543-557

  3. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

    Frontiers in Oncology, Vol. 9

  4. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease

    European Journal of Cancer, Vol. 130, pp. 228-240

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

  2. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

    Obstetrical and Gynecological Survey

  3. Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer

    Future Oncology, Vol. 15, Núm. 3, pp. 271-280

  4. Una revisión sistemática de las recomendaciones diagnósticas y terapéuticas del panel de expertos en cáncer de origen desconocido

    Archivos de medicina, Vol. 15, Núm. 1

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

    Annals of Oncology, Vol. 29, Núm. 4, pp. 910-916

  3. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

    The Lancet Oncology, Vol. 19, Núm. 12, pp. 1680-1687